Business Context and Reporting Period
This Form 8-K filing by Bone Biologics Corp (BBLG) covers the reporting period of October 1, 2024. The company is incorporated in Delaware and trades on the Nasdaq Capital Market under the symbols BBLG (Common Stock) and BBLGW (Warrants).
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on corporate governance changes rather than financial performance.
Material Changes
On October 1, 2024, Don Hankey resigned as a director of the Company, effective immediately. The Company stated that Mr. Hankey's departure was not due to any disagreement with the Company regarding its operations, policies, or practices.
Guidance, Outlook, and Risks
The filing contains no guidance, outlook, management commentary on future operations, or discussion of risks and contingencies. No unusual items were reported in this document.
Investor Verification Checklist
- Verify the current composition of the Board of Directors following Mr. Hankey's resignation.
- Confirm whether the Board has initiated a search for a replacement director.
- Review recent 10-Q or 10-K filings for the most up-to-date financial metrics, as this 8-K does not contain them.